• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Review, Q2 2011 - Product Image

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Review, Q2 2011

  • ID: 1841889
  • June 2011
  • 39 pages
  • Global Markets Direct

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Review, Q2 2011', provides an overview of the Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) therapeutic pipeline. This report provides information on the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease). 'Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Overview
Therapeutics Development
An Overview of Pipeline Products for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Therapeutics under Development by Companies
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Therapeutics - Products under Development by Companies
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Therapeutics Development
Genzyme Corporation
Actelion Ltd
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Acid Sphingomyelinase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zavesca - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Busulfan + Cyclophosphamide + Antithymocyte Globulin + Hematopoietic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Campath + Busulfan + Cyclophosphamide + Hematopoietic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hematopoietic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Acetyl Cysteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Therapeutics – Drug Profile Updates
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) - Featured News
Nov 09, 2010: Actelion Receives Approval For Zavesca For Reimbursement Under Ontario Public Drug Program
Jan 12, 2010: Actelion Receives Positive Vote From FDA's Endocrinologic And Metabolic Drugs Advisory Committee For Zavesca For Treatment Of Niemann-Pick type C Disease
May 28, 2009: Poniard Unveils Positive Picoplatin Safety Profile
Jan 29, 2009: Zavesca (miglustat) receives EU approval for the treatment of progressive neurological manifestations in patients with Niemann-Pick type C disease
Dec 19, 2008: Miglustat (Zavesca) receives positive opinion from the European Committee for Medicinal Products for Human Use for an extension of indication for Niemann-Pick type C disease
Jul 02, 2007: Alkermes Announces Positive Results From Phase I/II Clinical Study Of ALKS 29
Mar 26, 2007: RegeneRx Reports Preliminary Cardiovascular Data At Thymosin Meeting
Aug 01, 2006: NIH Researchers Find RegeneRx's Drug Candidate Regulates Key Proteins Important In Wound Repair
May 19, 2005: NIH Scientist Reports Wound Healing Effects Of Tß4
Oct 08, 2003: RegeneRx Successfully Completes Phase 1 Clinical Trial With Novel Wound Healing Drug, RGN-352
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), Q2 2011
Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Genzyme Corporation, 2011
Actelion Ltd, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease), Q2 2011
Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos